Category: Pharma Industry

UPDATE Monday, Feb. 14, 2022, 1:30 p.m. EST—The U.S. Health Resources and Services Administration (HRSA) said, “We are reviewing GSK’s policy and will evaluate next steps as needed.”

Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective

Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.

Earlier

Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.

Real Chemistry, a health sector communications consulting firm, published

Drug industry technology company Kalderos, which has struggled to launch its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate instead of as an up-front discount, has a new chief executive officer.

The company announced

Biopharmaceutical company Vertex is providing refunds to 340B covered entities for overcharges on its cystic fibrosis (CF) combination medicine Trikafta for the period from Q2 2021 through Q4 2021, according to a public notice on the U.S. Health Resources and

UPDATE Friday, Jan. 28, 2022, 3:25 p.m.—The U.S. Health Resources and Services Administration (HRSA) said this afternoon it is reviewing Pfizer’s policy and will evaluate next steps as needed.

Pfizer today became the 13^th drug manufacturer to impose conditions on

Drug manufacturer Novo Nordisk has amended its policy restrictions on 340B drug sales to hospitals involving shipments to contract pharmacies.

In a notice to covered entities dated Jan. 24, Novo Nordisk said if a 340B hospital covered entity “does